Hackensack, New Jersey Clinical Trials

A listing of Hackensack, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 258 clinical trials
UAT_Local 01-19-May  

This is for UAT_Local 01-19-May.

Online studies
Accepts healthy volunteers
UAT-UK
(online study)
  • 0 views
  • 19 May, 2025
  • 1 location
  • Online study
Test

In this prospective cohort study, 250 patients with suspected or known CAD and at least one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than 0.80 underwent coronary computed tomography angiography (CCTA) with NiFFR assessment. Patients were followed for one year to monitor for MACE

Online studies
  • 0 views
  • 28 Aug, 2025
  • Online study
Social & QoL Behaviors in Parkinson's Disease

Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same …

Online studies
Accepts healthy volunteers
  • 0 views
  • 02 Apr, 2026
  • Online study
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

renal function test
hepatitis
systemic therapy
human chorionic gonadotropin
experimental therapy
Hackensack University Medical John Theurer Cancer Center
 (0.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

hodgkin's disease
systemic therapy
marginal zone lymphoma
lymphoma
b-cell lymphoma
Memorial Sloan Kettering Cancer Center
 (9.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +35 other locations
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

small cell lung cancer
atezolizumab
maintenance therapy
measurable disease
extensive stage sclc
Mount Sinai - PRIME; Icahn School of Medicine at Mount Sinai
 (8.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +146 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

macitentan
left ventricular end-diastolic pressure
right heart catheterization
patent ductus arteriosus
macitentan 10 mg
Columbia University
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +210 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

17p deletion
lymphoid leukemia
fludarabine
leukemia
bendamustine
Regional Cancer Care Associates
 (0.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +50 other locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO when given concomitantly with routine pediatric vaccines to infants and toddlers 6 …

Investigational Site Number 8400069
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +47 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

anastrozole
er-positive breast cancer
adenocarcinoma of the breast
tamoxifen
oestrogen receptor positive breast cancer
Investigational Site Number 8400025
 (0.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +130 other locations